Notably, TREM2, as a major immune checkpoint on TAMs (36), has also been linked to depletion of CD8+ tumor-infiltrating lymphocytes (TILs) and anti-PD-1 resistance in human cancers (17, 32, 37). Here, CD8A is linked to neoplasm.